Delivery Order SPE2DB20D1109-SPE2DB21FQ04G
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Veklury (Remdesivir) 100 mg vials. The $8,851.96 firm-fixed price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 between Amerisourcebergen and the DLA, which serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Veklury (Remdesivir) 100 mg vials, a critical COVID-19 treatment medication. The contract is a firm fixed-price Delivery Order with a ceiling value of $4,754.64 and an ultimate completion date of February 13, 2025. The contract is not set aside for any specific business category....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of 100 mg vials of the antiviral medication Veklury (Remdesivir). The $4,085.52 firm fixed-price delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen to provide a comprehensive range of pharmaceutical products and medical supplies in support of military healthcare programs globally. The contract does not have a...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The contract is for the supply of Veklury (Remdesivir) 100 mg vials, a treatment for COVID-19. The contract has a ceiling value of $6,809.20 and runs through July 31, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, with a ceiling value of $11,886.60. The contract is for the supply of VEKLURY (Remdesivir) 100 mg vials, a medication used to treat COVID-19. The contract is a firm fixed-price delivery order and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $4,754.64, is for the delivery of the drug VEKLURY (Remdesivir) 100 mg vials. It is a firm fixed-price contract with a completion date of June 2, 2025. The contract is not set aside for any particular business type. AmerisourceBergen Drug Corp holds a large Indefinite Delivery Contract (IDC) with DLA Troop Support...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of VEKLURY (Remdesivir) 100 mg vials. The contract has a ceiling value of $13,618.40 and a completion date of August 16, 2024. It is a firm-fixed-price contract. AmerisourceBergen, a major pharmaceutical distributor, is the prime contractor for this award. The contract supports the federal government's healthcare needs, likely supplying the VEKLURY medication to...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Veklury (Remdesivir) 100 mg vials. The total ceiling value of the contract is $3,169.76, with a period of performance through March 25, 2025. The contract is a firm-fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
- This federal contract award to Amerisourcebergen Drug Corp is a Delivery Order (SPE2DB20D3103|SPE2DB24FP6V0) worth $13,618.40 for the supply of 100 mg VEKLURY (Remdesivir) vials. The award was made by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of August 16, 2024. The contract is a Firm Fixed Price agreement with no set-aside designation, indicating open competition. Amerisourcebergen is a major pharmaceutical distributor and healthcare solutions...
- This federal contract award is for the delivery of VEKLURY (Remdesivir) 100 mg vials to the U.S. government. The $13,618.40 firm fixed price contract was awarded to AmerisourceBergen Drug Corp by the Defense Logistics Agency (DLA) Troop Support Medical, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. The contract has an ultimate completion date of September 18, 2024. AmerisourceBergen, a large pharmaceutical distributor, has been awarded...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB21FQ04GDelivery Order
This contract award, valued at $34,017.00, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Veklury (Remdesivir) 100 mg vials, a critical medication used in the treatment of COVID-19. The contract has a completion date of October 7, 2021 and utilizes a Firm Fixed Price pricing structure. AmerisourceBergen Drug Corp is a subsidiary of the parent company, Cencora, Inc., which holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This award does not have a set-aside designation, indicating open competition. The DLA is a defense agency responsible for providing logistics, acquisition, and technical services to the U.S. Armed Forces, which includes procuring and distributing essential medical supplies and pharmaceuticals.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.0k | 9/16/21 |